Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astagraf XL in HLA Sensitized Kidney Transplant Recipients
NCT03194321Phase 4Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2017
- Primary completion
- Oct 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by Cedars-Sinai Medical Center. Primary endpoint: Number of Participants With Treatment-related Adverse Events and Treatment Failure at 12 months. Started Sep 2017; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03194321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194321.